Regain your health

Immunotherapy with Allergens (Allergy Shots)


Immunotherapy is a long-term, preventive treatment that aims to reduce the symptoms of patients diagnosed with hay fever, allergic asthma, conjunctivitis, or allergies to insect stings. 

Hospital o serveis complementaris relacionats

General Hospital

Where to find it


The objective of immunotherapy with allergens is to change the allergic response by inducing immunological tolerance. A patient with allergies has symptoms when they are exposed to the relevant allergen. Immunotherapy uses a larger quantity of the allergen, in combination with a different route of entry into the body. This modifies the immune system's abnormal response, causing it to develop a tolerance to the allergen instead of inflammation and allergic symptoms. 

Immunotherapy was originally administered by subcutaneous injection.There are currently liquids or fast-dissolving tablets that can be used in sublingual immunotherapy for certain allergens.

Subcutaneously injected treatments are administered every 4 or 8 weeks; sublingual treatments must be administered daily. This is generally continued over a period of 3 to 5 years. Many patients experience a prolonged protective effect after that period, so an assessment may be made of stopping the immunotherapy. 


Who might need immunotherapy with allergens (allergy shots)? 

Immunotherapy is indicated for patients with allergic rhinoconjunctivitis or allergic asthma who:

  • Have symptoms that are not well controlled with drugs or avoidance measures.
  • Require high doses of medications, multiple medications, or both, to control the condition.
  • Experience adverse reactions to the medications.
  • Want to avoid long-term use of pharmacological treatments.

Immunotherapy with hymenoptera venom is indicated for individuals who experience a severe generalised reaction to bee or wasp stings.



Immunotherapy is generally safe and well tolerated when used in suitably selected patients. Even so, localised and generalised reactions can occur. 

The most frequent reactions are localised ones, such as redness or itching at the injection site. These reactions are most likely to occur during the first administration of the treatment, which is why immunotherapy starts at the Allergology Department and, if well tolerated, can be continued on an outpatient basis. 

Related professionals
Dra. Victòria
Cardona Dahl
Head of Department
Dra. Mar
Guilarte Clavero
Sra. Patricia
García Ortega
Sra. Eugènia
Sr. Lucas
Rivera Sánchez
Dr. Moisés
Labrador Horrillo
Sra. Carla
Alonso Martínez
Dra. Anna
Sala Cunill
Sra. Emilia
Cid Rodríguez
Dra. Ingrid Johana
Gil Serrano